Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors

J Biol Chem. 2002 Feb 15;277(7):5411-7. doi: 10.1074/jbc.M105326200. Epub 2001 Nov 27.

Abstract

Mitochondrial dysfunction has been associated with Parkinson's disease. However, the role of mitochondrial defects in the formation of Lewy bodies, a pathological hallmark of Parkinson's disease has not been addressed directly. In this report, we investigated the effects of inhibitors of the mitochondrial electron-transport chain on the aggregation of alpha-synuclein, a major protein component of Lewy bodies. Treatment with rotenone, an inhibitor of complex I, resulted in an increase of detergent-resistant alpha-synuclein aggregates and a reduction in ATP level. Another inhibitor of the electron-transport chain, oligomycin, also showed temporal correlation between the formation of aggregates and ATP reduction. Microscopic analyses showed a progressive evolution of small aggregates of alpha-synuclein to a large perinuclear inclusion body. The inclusions were co-stained with ubiquitin, 20 S proteasome, gamma-tubulin, and vimentin. The perinuclear inclusion bodies, but not the small cytoplasmic aggregates, were thioflavin S-positive, suggesting the amyloid-like conformation. Interestingly, the aggregates disappeared when the cells were replenished with inhibitor-free medium. Disappearance of aggregates coincided with the recovery of mitochondrial metabolism and was partially inhibited by proteasome inhibitors. These results suggest that the formation of alpha-synuclein inclusions could be initiated by an impaired mitochondrial function and be reversed by restoring normal mitochondrial metabolism.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / metabolism
  • Animals
  • Blotting, Western
  • COS Cells
  • Cysteine Endopeptidases / pharmacology
  • Electron Transport
  • Electrons
  • Humans
  • In Situ Nick-End Labeling
  • Microscopy, Fluorescence
  • Mitochondria / metabolism*
  • Multienzyme Complexes / pharmacology
  • Nerve Tissue Proteins / chemistry*
  • Nerve Tissue Proteins / metabolism*
  • Proteasome Endopeptidase Complex
  • Protein Conformation
  • Recombinant Proteins / metabolism
  • Rotenone / pharmacology
  • Synucleins
  • Time Factors
  • Tubulin / metabolism
  • Ubiquitin / pharmacology
  • Uncoupling Agents / pharmacology
  • Vimentin / metabolism
  • alpha-Synuclein

Substances

  • Multienzyme Complexes
  • Nerve Tissue Proteins
  • Recombinant Proteins
  • SNCA protein, human
  • Synucleins
  • Tubulin
  • Ubiquitin
  • Uncoupling Agents
  • Vimentin
  • alpha-Synuclein
  • Rotenone
  • Adenosine Triphosphate
  • Cysteine Endopeptidases
  • Proteasome Endopeptidase Complex